DekaBank Deutsche Girozentrale Acquires 1,775 Shares of Exact Sciences Co. (NASDAQ:EXAS)

DekaBank Deutsche Girozentrale raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 3.1% during the second quarter, HoldingsChannel reports. The fund owned 59,891 shares of the medical research company’s stock after purchasing an additional 1,775 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Exact Sciences were worth $2,680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Asahi Life Asset Management CO. LTD. raised its holdings in Exact Sciences by 4.2% during the 4th quarter. Asahi Life Asset Management CO. LTD. now owns 4,390 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 175 shares during the period. Perigon Wealth Management LLC increased its holdings in shares of Exact Sciences by 2.1% in the first quarter. Perigon Wealth Management LLC now owns 8,516 shares of the medical research company’s stock worth $588,000 after purchasing an additional 175 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Exact Sciences by 65.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock worth $31,000 after purchasing an additional 179 shares during the period. Sanders Morris Harris LLC increased its holdings in shares of Exact Sciences by 4.2% in the first quarter. Sanders Morris Harris LLC now owns 5,000 shares of the medical research company’s stock worth $345,000 after purchasing an additional 200 shares during the period. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Exact Sciences by 1.7% in the first quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock worth $825,000 after purchasing an additional 200 shares during the period. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $69.21 on Thursday. The company has a 50-day simple moving average of $55.85 and a two-hundred day simple moving average of $55.58. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The firm has a market cap of $12.77 billion, a price-to-earnings ratio of -52.43 and a beta of 1.26.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.28. The business had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The company’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.45) earnings per share. On average, equities analysts forecast that Exact Sciences Co. will post -0.87 EPS for the current year.

Wall Street Analysts Forecast Growth

EXAS has been the topic of several research analyst reports. Evercore ISI decreased their price target on shares of Exact Sciences from $80.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $75.00 price target on shares of Exact Sciences in a report on Friday, September 13th. Stifel Nicolaus decreased their price target on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Benchmark decreased their price target on shares of Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, BTIG Research decreased their price target on shares of Exact Sciences from $80.00 to $70.00 and set a “buy” rating on the stock in a report on Wednesday, June 26th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $78.14.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.